Cellectar Biosciences

Learn more about the pediatric HGG clinical study at

[Cellectar Biosciences @CellectarBio]

James Caruso, CEO of Cellectar Biosciences, comments on the Company's Q3 2026 financial results and corporate updates. For recent corporate highlights and upcoming key milestones, visit: https://t.co/fOjdaVNbtx $CLRB

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences announced financial results for the quarter ended September 30, 2026, and provided a corporate update. Read the full announcement: https://t.co/fOjdaVNbtx $CLRB

[Cellectar Biosciences @CellectarBio]

Reminder: $CLRB will report financial results for the third quarter ended September 30, 2026, and provide a corporate update tomorrow, November 10, at 8:30 a.m. ET. For webcast details: https://t.co/BsG7pSZkEL

[Cellectar Biosciences @CellectarBio]

Sikander Ailawadhi, MD, of @MayoClinic will present updated 12-month follow-up data from the Phase 2b CLOVER WaM clinical trial evaluating iopofosine I 131 in WM at #ASH26 on Dec. 14, from 6:00–8:00 p.m. in New Orleans, LA (Poster #5325). https://t.co/SRATLsrzey $CLRB

[Cellectar Biosciences @CellectarBio]

These findings strengthen the clinical rationale for iopofosine I 131 in r/r WM and support its potential evaluation in earlier treatment settings, where substantial unmet need remains. https://t.co/SRATLss746 $CLRB

[Cellectar Biosciences @CellectarBio]

$CLRB announced that three posters highlighting compelling data & clinical progress for its lead candidate, iopofosine I 131 in WM, will be presented at the upcoming @ASH_hematology Annual Meeting and Exposition held Dec. 12–15 in NOLA. https://t.co/SRATLss746 #ASH26

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m. ET. For more info: https://t.co/sZ3TGIbIIO $CLRB

[Cellectar Biosciences @CellectarBio]

$CLRB CEO James Caruso comments on reported case study results highlighting that a single administration of iopofosine I 131 produced a durable complete response lasting more than eight years in a heavily pretreated patient w/ aggressive, relapsed DLBCL. https://t.co/FGZUxgvGkm

[Cellectar Biosciences @CellectarBio]

Jarrod Longcor, COO of $CLRB, comments on the Company's recently reported DLBCL case study results, highlighting the broader potential of iopofosine I 131 across B-cell malignancies. https://t.co/FGZUxgvGkm

[Cellectar Biosciences @CellectarBio]

$CLRB reported case study results highlighting a durable complete response lasting more than eight years following a single administration of iopofosine I 131 in a heavily pretreated patient with aggressive, relapsed diffuse large B-cell lymphoma. https://t.co/FGZUxgvGkm

[Cellectar Biosciences @CellectarBio]

Jarrod Longcor, Cellectar COO, comments on efficacy data from Phase 2b CLOVER WaM subset analysis of iopofosine I 131 in patients R/R to BTK inhibitor therapy, presented today at #IWWM13: https://t.co/QcuhhyycZ5 $CLRB

[Cellectar Biosciences @CellectarBio]

$CLRB announced Ph. 2b CLOVER WaM subgroup efficacy results presented at #IWWM13. The subgroup analysis of patients who received BTKi treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months. https://t.co/QcuhhyycZ5

[BioForward @BioForward]

NEW: Wisconsin-based @NMRadioisotopes will partner with @CellectarBio 🌟

This new partnership will integrate NorthStar's Ac-225 into Cellectar's proprietary PLE delivery platform for groundbreaking cancer treatments.

#Biotech #CancerResearch #WisconsinInnovation

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 https://t.co/G8TJn2H0y9 $CLRB

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences and @SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer https://t.co/mizirMBl26

[Cellectar Biosciences @CellectarBio]

Today, around the U.S., we pause to honor the service and sacrifice of our veterans. At Cellectar Biosciences, we are grateful for those who have bravely served our country and are proud to support our nation's heroes.💙❤️

#VeteransDay #SupportOurVeterans #Community $CLRB

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

https://t.co/908lQW4pmk #ConferenceCall #Cellectar $CLRB

[Cellectar Biosciences @CellectarBio]

Do you or someone you love have #HighGradeGlioma? Please consider our #PediatricClinicalTrial:
https://t.co/G8ACrMMTiY. Check out @TeamJack for more information about childhood brain cancer. #endbraintumors #CancelChildhoodCancer #pediatricbraintumor #curethekids $CLRB

[Cellectar Biosciences @CellectarBio]

If your child has been diagnosed with High-Grade Glioma, ask your doctor about our clinical trial for #HGG at https://t.co/G8ACrMMTiY. Thank you to @PCRF_Kids for this very informative infographic. #PediatricBrainCancer #defeatDIPG #ChildhoodCancer $CLRB

[Cellectar Biosciences @CellectarBio]

🧬 Amazing talks and insights on Waldenstrom's at the IWWM Conference this week. Every step in research brings us closer advances for patient care! #IWWM2024 #CancerResearch #Prague #WMResearch #WaldenstromsMacroglobulinemia #Lymphoma $CLRB